Reproductive System Agents Flashcards
teratogens
substances that cause developmental abnormalities in the fetus
therapeutic uses of estrogen/progestin (5)
- contraception
- menopausal therapy
- anti-estrogen used for hormone-responsive breast cancer and infertility
- anti progestin used for medical abortion
- other non-contraceptive uses: menstrual cycle issues, acne
physiologic mechanism of oral contraceptives (3)
- suppresses pituitary secretion of FSH and LH (decreased stimulation of follicle develpment and ovulation)
- creates changes in the endometrium to make it less favorable for implantation of fertilized ovum
- changes quantity and viscosity of cervical mucus to make it hostile to sperm
monophasic BCPs
- most common
- fixed ratio of estrogen to progestin throughout cycle
biphasic BCPs
fixed estrogen, varied progesterone
triphasic BCPs
- newest combination pill
- low doses, few side effects
- either estrogen or progesterone varies during 3 phases
extended cycle BCPs
24 days of active hormonal therapy + 4 days of placebo (normal is 21 days + 7 days)
continuous dosing BCPs
- 28-day packets taken continuously without interruption for withdrawal menses - no placebos
- only 4 periods per year with possible breakthrough bleeding
estrogen combination BCPs with drospirenone
estrogen (Ethinyl Estradiol) combined with progestin derived from spironolactone (Aldactone)
estrogen-drospirenone combination BCPs contraindications (3)
kidney, liver, or adrenal disease
what levels should be checked when taking drospirenone BCPs?
- potassium - may be increased due to diuretic property
- check esp. when taking with other drugs that increase K (NSAIDs, K-sparing diuretics, ACE inhibitors, ARBs, heparin)
ACHES
dangerous side effects of BCPs: A - abdominal pain (severe) C - chest pain, shortness of breath H - headache (severe), dizziness, weakness, numbness, speech difficulties E - eye disorders S - severe leg pain, calf/thigh swelling
rare side effects of BCPs
thromboembolism, PE, MI, CVA, retinal thrombosis
hormone therapy indications
- estrogen-progestin therapy (EPT) for use with women who have an intact uterus
- estrogen therapy (ET) for use with women who have had a hysterectomy (removal of uterus)
- cross-sex hormone therapies - to achieve congruence with gender identity
meds for treatment of osteoporosis (2)
- biophosphonates - slows bone resorption
- selective estrogen receptor modulators (SERMs)